Analysts Set Bausch Health Cos Inc. (NYSE:BHC) Target Price at $8.33

Bausch Health Cos Inc. (NYSE:BHC) has been assigned an average recommendation of “Reduce” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $8.3333.

Several equities research analysts have commented on BHC shares. Truist Financial upped their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a report on Wednesday, January 7th. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Barclays cut their price objective on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, February 25th. Finally, Weiss Ratings lowered shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th.

Bausch Health Cos Stock Performance

NYSE BHC opened at $5.55 on Tuesday. The company has a market cap of $2.07 billion, a P/E ratio of 13.20 and a beta of 0.40. The company has a fifty day simple moving average of $5.54 and a 200 day simple moving average of $6.22. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a 12-month low of $4.41 and a 12-month high of $8.69.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 18th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The company had revenue of $2.78 billion during the quarter, compared to analysts’ expectations of $2.71 billion. Sell-side analysts predict that Bausch Health Cos will post 4.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new position in Bausch Health Cos in the first quarter worth $68,000. Jones Financial Companies Lllp lifted its stake in Bausch Health Cos by 1,548.9% during the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock worth $162,000 after purchasing an additional 23,451 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Bausch Health Cos by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after purchasing an additional 467,270 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Bausch Health Cos by 3.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after purchasing an additional 9,834 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Bausch Health Cos by 11.2% in the 2nd quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock worth $5,597,000 after purchasing an additional 84,892 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.